<DOC>
	<DOCNO>NCT02266420</DOCNO>
	<brief_summary>This prospective , non-randomized multicenter study design compare biological feature pN0 triple negative breast cancer ( TNBC ) size ≤ 10 mm ( pT1a/b ) versus pT1c T2 ≤ 30 mm . All consecutive patient recruit investigator completion surgery . No modification standard management accord investigator center do . All patient follow year 5 year order collect follow event : local loco regional recurrence , metastatasis , second cancer , death cause . At initial visit , 10 mL blood sample collect ( = study intervention ) immediately process serum storage ; serum sample store -80°C may use purpose scientific research . A representative formalin-fixed paraffin-embedded tumor block 200 sample address Institut Claudius Regaud central collection consist one haematoxylin-eosin stain slide central histological review , 15 unstained slide DNA extraction ( microdissection ) , construction tissue micro-array ( TMA ) . Extracted DNA 100 sample ( 50 group ) transfer Institut Paoli Calmettes , Marseille ; extract DNA subject array-CGH analysis order detect gene copy number alteration gains/amplifications/deletions , next generation sequencing ( NGS ; MiSeq , Illumina ) use panel ~400 gene mutation detection .</brief_summary>
	<brief_title>Comparison Biological Features Between pN0 Triple Negative Breast Tumours With Size &lt; = 10 mm ( pT1a/b ) Versus pT1c T2 &lt; = 30 mm</brief_title>
	<detailed_description />
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Woman age ≥ 18 year . 2 . Patient complete surgery breast cancer definitive histopathological analysis surgical specimen available . 3 . Invasive breast carcinoma pN0 pN ( i+ ) histological tumor size ≤ 10 mm ( pT1a/b subgroup ) invasive breast carcinoma histological tumor size &gt; 10 mm ≤ 30 mm ( pT1c T2 ≤ 30 mm control group ) . 4 . Patient HER2negative breast carcinoma : immunohistochemistry ( IHC ) score = 0 , 1+ 2+ situ hybridization ( FISH , CISH , SISH ) negative ( local laboratory test ) . 5 . Patient ER PR negative invasive carcinoma ( &lt; 1 % stained cell immunohistochemistry assay ) ( local laboratory test ) . 6 . In case multifocality , histological size large tumor must ≤ 10 mm ≤ 30 mm accord inclusion subgroup . All lesion must ER , PR HER2negative . 7 . In case breast conserving surgery , clear margin require . 8 . Patient affiliate Social Health Insurance France . 9 . Patient information write informed consent form sign prior study specific procedure . 1 . Patients previous malignancy breast site , exception adequately treat basal squamous cell carcinoma , nonmelanomatous skin cancer totally resect . 2 . Noninvasive breast carcinoma ( i.e . ductal carcinoma situ exclusively ) . 3 . Inoperable breast invasive carcinoma . 4 . Synchronous bilateral breast cancer . 5 . Patients receive neoadjuvant treatment ( radiotherapy chemotherapy surgery ) . 6 . Pregnant breastfeed woman . 7 . Any psychological , familial , geographic social situation , accord judgment investigator , potentially prevent provision inform consent compliance study procedure . 8 . Patient forfeit his/her freedom administrative legal award guardianship .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>immuno-histochemistery</keyword>
	<keyword>genomic profile</keyword>
</DOC>